The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

Exelixis EXEL has put up a stellar performance so far this year. Shares of the biotech company have rallied 35.2% in the past three months compared with the industry’s growth of 11.8%. The stock has ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death, the company said.

The trial is sponsored by Genentech and co-funded by Jazz Pharmaceuticals. About Tecentriq ® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1.

Tecentriq may be used with the chemotherapy medicines carboplatin and etoposide as your first treatment when your lung cancer: is a type called “extensive-stage small cell lung cancer,” which ...

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.

Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza, a subcutaneous anti-PD-(L)1 cancer immunotherapy. The treatment offers a quicker and more comfortable ...

Basel, 13 September 2024- Roche announced today that the U.S. Food and Drug Administration has approved Tecentriq Hybreza TM, the first and only PD- 1 inhibitor for subcutaneous, under the skin ...

With Tecentriq Hybreza and Roche/Genentech’s 13 other subcutaneous therapies – available across various diseases – we offer additional administration options to meet the diverse preferences ...